Journal: The Journal of Prevention of Alzheimer's Disease
Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort
doi: 10.1016/j.tjpad.2026.100502
Figure Lengend Snippet: Diagnostic performance and cutoff points of plasma p-tau217 biomarkers for detecting amyloid pathology ( A ) ROC curves showing the AUCs of each plasma biomarker in discriminating amyloid pathology, as defined by the CSF Aβ42/Aβ40 ratio. ( B ) Simoa p-tau217, ( C ) Lumipulse p-tau217, and ( D ) Lumipulse p-tau217/Aβ42 × 10³ plots are shown. The red solid lines indicate the single-point cutoffs determined by the maximum Youden index. The red dashed lines represent the two-point cutoffs achieving >95% sensitivity and >95% specificity, with the intermediate zones shaded in red. For Lumipulse p-tau217, only one cutoff is shown as it meets both criteria using a single threshold. For Lumipulse p-tau217/Aβ42, the single-point and two-point cutoffs were identical, and thus only the red solid line is displayed. FDA-approved two-point cutoffs are indicated by blue dashed lines, with the intermediate zones shaded in blue.
Article Snippet: • Plasma p-tau217 values showed a correlation between LUMIPULSE and Simoa platforms.
Techniques: Diagnostic Assay, Clinical Proteomics, Biomarker Discovery